Genmab stock surges 16% on positive cancer trial results
Summary
Shares of Genmab experienced a significant increase following favorable outcomes from a recent cancer study. The stock value rose by sixteen percent as investors reacted to the positive clinical trial data.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.